ABEONA THERAPEUTICS INC.
ABEONasdaq
$7.00
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +11.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$396.3M
Enterprise Value
$246.2M
P/E
7.4
P/S
—
P/B
2.7
EV/EBITDA
—
PEG
—
FCF Yield
-21.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$76.2M
Free Cash Flow (TTM)
-$85.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-52.6%
ROIC
—
Debt / Equity
0.1
Net Cash
$150.2M
Return 1Y
+5.6%
Company profile
Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.
- CEO
- Vishwas Seshadri
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Ohio
- Website
- abeonatherapeutics.com
Management & directors
- O'Malley Brendan M.SVP, Chief Legal Officer
- Seshadri VishwasChief Executive Officer
- Vasanthavada MadhavChief Commercial Officer
- Vazzano Joseph WalterChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ABEO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.7M—
Diluted EPS-$0.30↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | $3.0M | $1.4M | $3.5M | — | $5.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$81.4M | -$89.8M | -$50.9M | -$47.1M | -$64.2M | -$89.4M |
| Net income | -$84.2M | -$84.9M | -$39.7M | $54.2M | $63.7M | -$71.2M |
| Diluted EPS | — | — | -$5.53 | -$2.53 | -$1.55 | $1.01 |
| Operating cash flow | -$35.0M | -$65.7M | -$43.5M | -$37.0M | -$56.0M | -$76.3M |
| Free cash flow | -$36.4M | -$69.8M | -$43.6M | -$37.3M | -$58.5M | -$84.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -814.2% | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Net margin | -842.3% | -2831.2% | -2807.4% | 1548.2% | — | -1223.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $400,000.00 | $0.00 | — | $8.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.9M | -$15.3M | -$16.7M | -$19.7M | -$22.8M | -$24.0M | -$22.9M | -$23.0M |
| Net income | $7.4M | -$30.3M | $118.2M | -$12.0M | $108.8M | -$5.2M | -$162.8M | -$17.1M |
| Diluted EPS | -$0.26 | -$0.63 | $0.50 | -$0.24 | $1.71 | -$0.10 | -$0.36 | -$0.30 |
| Operating cash flow | -$12.7M | -$12.2M | -$16.6M | -$18.4M | -$18.8M | -$21.2M | -$18.0M | -$19.8M |
| Free cash flow | -$13.4M | -$12.6M | -$17.2M | -$19.8M | -$21.7M | -$23.7M | -$19.1M | -$20.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -5698.0% | — | — | -264.1% |
| Net margin | — | — | — | — | 27208.3% | — | — | -195.8% |
Company news
Jun 10, 2026
Jun 8, 2026
Jun 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Seshadri Vishwas· Chief Executive Officer | Sale | 67,971 | $6.96 | $473,329.65 | filing |
| 2026-07-09 | Vazzano Joseph Walter· Chief Financial Officer | Sale | 24,880 | $6.96 | $173,256.86 | filing |
| 2026-07-09 | Vasanthavada Madhav· Chief Commercial Officer | Sale | 12,606 | $6.96 | $87,784.40 | filing |
| 2026-07-09 | O'Malley Brendan M.· SVP, Chief Legal Officer | Sale | 12,050 | $6.96 | $83,912.59 | filing |
| 2026-06-30 | Alland Leila | Sale | 11,000 | $5.92 | $65,087.00 | filing |
| 2026-06-16 | Vasanthavada Madhav· Chief Commercial Officer | J | 222 | $5.67 | $1,258.74 | filing |
| 2026-06-15 | Silverstein Christine Berni | Sale | 18,160 | $5.71 | $103,695.42 | filing |
| 2026-06-09 | Seshadri Vishwas· Chief Executive Officer | Sale | 31,916 | $5.30 | $169,288.85 | filing |
| 2026-06-09 | Vazzano Joseph Walter· Chief Financial Officer | Sale | 25,646 | $5.39 | $138,288.36 | filing |
| 2026-06-09 | Vazzano Joseph Walter· Chief Financial Officer | Sale | 13,421 | $5.30 | $71,187.67 | filing |
| 2026-06-09 | O'Malley Brendan M.· SVP, Chief Legal Officer | Sale | 6,305 | $5.30 | $33,442.98 | filing |
| 2026-06-09 | Vasanthavada Madhav· Chief Commercial Officer | Sale | 5,450 | $5.30 | $28,907.89 | filing |
| 2026-06-08 | Seshadri Vishwas· Chief Executive Officer | Sale | 24,428 | $5.43 | $132,631.83 | filing |
| 2026-06-08 | Vazzano Joseph Walter· Chief Financial Officer | Sale | 10,271 | $5.43 | $55,766.39 | filing |
| 2026-06-08 | O'Malley Brendan M.· SVP, Chief Legal Officer | Sale | 4,826 | $5.43 | $26,202.77 | filing |
| 2026-06-08 | Vasanthavada Madhav· Chief Commercial Officer | Sale | 4,170 | $5.43 | $22,641.02 | filing |
| 2026-05-26 | Alvino Mark | Gift | 500 | $0.00 | $0.00 | filing |
| 2026-05-22 | Alvino Mark | Sale | 6,500 | $5.46 | $35,462.70 | filing |
| 2026-05-15 | Crombez Eric | Sale | 26,143 | $5.53 | $144,636.15 | filing |
| 2026-05-11 | Vasanthavada Madhav· Chief Commercial Officer | Sale | 5,548 | $5.96 | $33,073.29 | filing |
| 2026-04-01 | Goldan Keith A. | Award | 32,751 | $0.00 | $0.00 | filing |
| 2026-03-31 | Seshadri Vishwas· Chief Executive Officer | Sale | 29,985 | $4.38 | $131,481.23 | filing |
| 2026-03-16 | Vazzano Joseph Walter· Chief Financial Officer | Sale | 785 | $4.76 | $3,736.60 | filing |
| 2026-02-02 | Silverstein Christine Berni | Sale | 20,070 | $5.09 | $102,168.34 | filing |
| 2026-02-02 | Alland Leila | Sale | 18,065 | $5.09 | $91,961.69 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.